A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
B-cell Malignancy|Marginal Zone Lymphoma|Follicular Lymphoma|Non-Hodgkin Lymphoma|Waldenström Macroglobulinemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Diffuse Large B Cell Lymphoma
DRUG: BGB-16673
Phase 1: Number of Participants with Adverse Events (AEs), Number of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) including results from laboratory assessments, electrocardiograms (ECGs), and physical examinations, and that meet protocol-defined dose-limiting toxicities (DLTs); as graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0., From the first dose of BGB-16673 until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)|Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-16673, MTD is defined as the highest evaluated dose with an estimated toxicity rate closest to the target, while MAD is the highest dose given if MTD is not reached., Approximately 28 days|Phase 1: Recommended dose(s) for Expansion (RDFE) of BGB-16673, RDFE of BGB-16673 alone will be determined based upon the MTD or MAD., Approximately 28 days|Phase 2: Overall response rate (ORR), Defined as the percentage of participants achieving a best overall response of partial response (PR) or better, assessed by the Independent Review Committee for participants with R/R CLL/SLL and R/R MCL and by the investigator for other cohorts (R/R WM, R/R FL, R/R non-GCB DLBCL, R/R Ritchter's transformation to DLBCL), evaluated using the Lugano criteria for NHL and SLL, iwCLL criteria for CLL, and IWWM-6 criteria for WM., approximately 3 years
Single dose and steady-state maximum observed plasma concentration (Cmax) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state minimum observed plasma concentration (Cmin) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state time to reach Cmax (tmax) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state time to reach half of Cmax (T1/2) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state area under the plasma concentration-time curve (AUC) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state apparent total clearance of drug from plasma after oral administration (CL/F) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state apparent volume of distribution (Vz/F) of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Single dose and steady-state accumulation ratios of BGB-16673, Week 1 Day 1 pre-dose; 2, 4, 6, 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose; and 2, 4, 6, 8 post-dose; Week 9 Day 1 pre-dose.|Bruton's tyrosine kinase (BTK) protein degradation in peripheral blood after BGB-16673 monotherapy, Week 1 Day 1 pre-dose; 8, 24, 48, and 72 hours post-dose; Week 5 Day 1 pre-dose and 8 hours post-dose; Week 9 Day 1 pre-dose.|Phase 1: Overall response rate (ORR), Defined as the percentage of participants whose best overall response is better than stable disease, as assessed by the investigator and evaluated according to the following criteria: the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for R/R CLL, the International Workshop on Waldenström's Macroglobulinemia (IWWM-6) criteria for R/R WM, and the Lugano criteria for R/R NHL., approximately 3 years|Phase 1: Number of R/R WM Participants with major response rate (MRR), MRR is defined as the percentage of participants whose best overall response (BOR) is partial response (PR) or better (PR, very good partial response (VGPR), or complete response (CR)) as assessed by the investigator and evaluated per the IWWM-6 criteria., approximately 3 years|Phase 1: Number of Participants with AEs in part 1e (Japan-only cohort ), Number of Japanese participants in Part 1e with TEAEs and SAEs, including results from laboratory assessments, ECGs, and physical examinations, that meet protocol-defined DLTs, graded according to the NCI-CTCAE v5.0., From the first dose of BGB-16673 in Part 1e until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (approximately 3 years)|Phase 2: Recommended Phase 2 Dose (RP2D), Defined as the dose of a drug recommended for use in Phase 2 clinical trials, the Recommended Phase 2 Dose (RP2D) is determined by the sponsor based on the Safety Monitoring Committee's recommendations, taking into account the overall clinical safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data., approximately 3 years|Phase 2: Number of Participants with AEs, Number of participants with TEAEs and SAEs, including results from laboratory assessments, ECGs, and physical examinations, that meet protocol-defined DLTs, graded according to the NCI-CTCAE v5.0., From the first dose of BGB-16673 in Phase 2 until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (approximately 3 years)|Phase 2: Complete Response Rate (CRR), CRR for participants in Cohort 2 (R/R blastoid or nonblastoid variant R/R MCL) is defined as the percentage of participants who achieve a complete response (CR), as determined by both the Independent Review Committee (IRC) and investigators., approximately 3 years|Phase 2: Response rate of minor response or better, Defined as the percentage of participants who achieve at least a minor response (MR) or a more favorable outcome, as assessed by investigators for cohort 3 (R/R WM), approximately 3 years|Phase 2: Duration of Response (DOR), DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is documented or death, whichever comes first as assessed by the investigator and the IRC., approximately 3 years|Phase 2: Time to Response (TTR), TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better), as assessed by IRC and the investigator, approximately 3 years|Phase 2: Progression- Free Survival (PFS), PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by IRC and the investigator, approximately 3 years|Phase 2: Overall Survival (OS), OS is defined as the time from first study drug administration to the date of death due to any cause, approximately 3 years|Phase 2: Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionaire, Mean change from baseline in the 'physical well-being' and 'functional well-being' subscales of the FACT-Leu for Cohort 1 participants (R/R CLL/SLL). FACT-Leu is a 44-item PRO questionnaire with five subscales used to measure health-related quality of life (HRQoL) in leukemia patients., Baseline and day 1 of Weeks 5, 13, 25, and 37|Phase 2: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 (NFLymSI-18), Mean change from baseline in the NFlymSI-18 subscales of disease-related symptoms (DRSP) and 'treatment side effects' for Cohort 2 participants (R/R MCL). The NFlymSI-18 is an 18-item patient-reported outcome (PRO) tool specifically designed to assess symptoms and treatment impacts in patients with non-Hodgkin lymphoma., Baseline and day 1 of Weeks 5, 13, 25, and 37
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)